Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of mRNA-1403 for prevention of norovirus acute gastroenteritis in adults
jRCT2031240456Phase 3Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 3, randomised, double-blind trial in Noroviral gastroenteritis comparing mRNA-1403 with Placebo (2 arms). Primary endpoints: Number of participants with solicited local and systemic adverse reactions, Number of participants with unsolicited adverse events and 3 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
mRNA-1403
03
Conditions
Noroviral gastroenteritis
Beyond the preview
Go deeper on jRCT2031240456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240456.